Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2023 Financial Results
Retrieved on:
Tuesday, February 27, 2024
FAP, Senior, Research, FPI, Chemistry, Neuroscience, AXIN1, Part, Death, LLM, Software as a service, Hemangioma, Genetics, Cancer, Software, Letter, Business operations, Data, Matchmaker, APC, Machine learning, Real space, Biology, Development, Partnership, Therapy, Enamine, CCM, Myrexis, Library, Drug discovery, Safety, Biomarker, Clinical trial, IND, Clostridioides difficile infection, Roche, NF2, Biotechnology, Neurofibromatosis type II, Trial of the century, LILAC, Disease, Myriad Genetics, Administration, Pharmaceutical industry
SALT LAKE CITY, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today reported business updates and financial results for its fourth quarter and fiscal year ending December 31, 2023.
Key Points:
- SALT LAKE CITY, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today reported business updates and financial results for its fourth quarter and fiscal year ending December 31, 2023.
- Research and Development Expenses: Research and development expenses were $69.5 million for the fourth quarter of 2023, compared to $44.0 million for the fourth quarter of 2022.
- General and Administrative Expenses: General and administrative expenses were $30.5 million for the fourth quarter of 2023 compared to $19.8 million for the fourth quarter of 2022.
- Net Loss: Net loss was $93.0 million for the fourth quarter of 2023, compared to a net loss of $57.5 million for the fourth quarter of 2022.